Brokerages Set Progyny, Inc. (NASDAQ:PGNY) Price Target at $28.55

Shares of Progyny, Inc. (NASDAQ:PGNY) have earned an average rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, ten have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $29.5455.

A number of research firms recently weighed in on PGNY. BTIG Research decreased their target price on shares of Progyny from $35.00 to $30.00 and set a “buy” rating for the company in a research report on Thursday, March 5th. Canaccord Genuity Group raised shares of Progyny from a “hold” rating to a “buy” rating and raised their target price for the company from $19.00 to $30.00 in a research report on Tuesday, May 19th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Progyny in a research report on Friday, March 27th. Truist Financial raised their target price on shares of Progyny from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $30.00 target price on shares of Progyny in a research report on Friday, March 6th.

Insider Activity

In other news, EVP Allison Swartz sold 4,657 shares of Progyny stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total value of $81,031.80. Following the completion of the transaction, the executive vice president owned 89,879 shares of the company’s stock, valued at $1,563,894.60. This trade represents a 4.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Melissa B. Cummings sold 9,578 shares of Progyny stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $25.00, for a total transaction of $239,450.00. Following the completion of the transaction, the chief operating officer directly owned 73,371 shares of the company’s stock, valued at approximately $1,834,275. This trade represents a 11.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 25,308 shares of company stock valued at $579,977 in the last quarter. Company insiders own 9.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of PGNY. Wellington Management Group LLP grew its position in shares of Progyny by 260.9% in the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after acquiring an additional 1,621,688 shares during the period. Fort Washington Investment Advisors Inc. OH grew its position in shares of Progyny by 46.9% in the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock valued at $45,734,000 after acquiring an additional 859,289 shares during the period. Loomis Sayles & Co. L P bought a new position in shares of Progyny in the 4th quarter valued at about $19,917,000. Barclays PLC grew its position in shares of Progyny by 79.2% in the 3rd quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock valued at $33,904,000 after acquiring an additional 696,447 shares during the period. Finally, Ameriprise Financial Inc. grew its position in shares of Progyny by 37.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after acquiring an additional 545,431 shares during the period. Institutional investors own 94.93% of the company’s stock.

Progyny Stock Performance

Progyny stock opened at $24.88 on Tuesday. The company has a market cap of $1.95 billion, a P/E ratio of 32.31, a price-to-earnings-growth ratio of 1.32 and a beta of 0.91. Progyny has a 1-year low of $16.10 and a 1-year high of $28.75. The company has a fifty day simple moving average of $19.21 and a 200 day simple moving average of $22.10.

Progyny (NASDAQ:PGNY) last released its earnings results on Thursday, May 7th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.03. The business had revenue of $328.50 million during the quarter, compared to the consensus estimate of $326.47 million. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The firm’s revenue for the quarter was down 26.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, equities research analysts forecast that Progyny will post 1.12 EPS for the current year.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.